{"id":102958,"title":"Avacta Group PLC (AIM:AVCT) Avacta to Present at Theranostics FAP Summit","publisher":"Share Talk","author":"sharetalk","published":"2022-10-31T14:28:09+00:00","modified":"2022-10-31T14:28:09+00:00","canonical_url":"https://www.share-talk.com/avacta-group-plc-aimavct-avacta-to-present-at-theranostics-fap-summit/","markdown_url":"https://www.share-talk.com/avacta-group-plc-aimavct-avacta-to-present-at-theranostics-fap-summit.md","json_url":"https://www.share-talk.com/avacta-group-plc-aimavct-avacta-to-present-at-theranostics-fap-summit.json","category":"Healthcare","categories":["Healthcare","Pharmaceutical"],"tags":["Abingdon Health","AffyXell Therapeutics","antigen","Avacta Group","AVCT","Biotherapeutics","Chris Yates","clinical","COVID-19","Cytiva","Daewoong Pharmaceutical","diagnostic","Doncaster","Europe","LG Chem Life Sciences","Pharma","radiopharmaceuticals","saliva test","SARS-COV-2","Sengho Jeon","South Korea","therapeutic","UK","validation","York"],"featured_image":"https://i0.wp.com/www.share-talk.com/wp-content/uploads/2023/11/Stencil-Google-Chrome-2023-04-19-at-2.47.43-PM.jpeg?fit=1231%2C615&ssl=1","format":"news","language":"en-GB","content":"**Avacta Group plc (AIM: AVCT),** a clinical stage biopharmaceutical company developing innovative cancer therapies and powerful diagnostics based on its proprietary Affimer® and pre|CISION™ platforms.\n\nAnnounces that it will be presenting at the Theranostics FAP Summit, organised by the International Centers for Precision Oncology Foundation, being held on 5 November 2022.\n\nThe online meeting will feature world-renowned experts in the biology of Fibroblast Activation Protein (FAP), which is highly expressed in cancer-associated fibroblasts (CAF) across many tumour types. Representatives from academia and industry will take a deep dive into the topic of FAP, its history and role in the biology of disease, the current state of research, and future applications in both diagnostics and therapeutic areas.\n\nAVA6000 is a form of the generic chemotherapy doxorubicin that has been modified using Avacta’s pre|CISION technology so that it is activated by FAP, predominantly in the tumour, with the aim of sparing healthy tissue from exposure and improving the safety, tolerability and efficacy of the drug. Avacta’s presentation, to be given by Dr Fiona Maclaughlin, Chief Scientific Officer of the Therapeutics division, will highlight the pre-clinical development of AVA6000.\n\nNo new information will be shared as part of the presentation.\n\nTitle: Pre-clinical Development of AVA6000 – a FAP targeted chemotherapeutic agent in Phase I\n\nDay/Date: Saturday, 5 November 2022\n\nTime: 17:30 – 17:45 CET\n\nSession number: VI\n\n-Ends-\n\nFor further information from Avacta Group plc, please contact:\n\n**Avacta Group plc**\n\nAlastair Smith, Chief Executive Officer\n\nTony Gardiner, Chief Financial Officer\n\nMichael Vinegrad, Group Communications Director\n\nTel: +44 (0) 1904 21 7070\n\n[www.avacta.com](http://www.avacta.com)"}